As­traZeneca’s asth­ma drug tralok­inum­ab goes 0 for 3 in PhI­II as 2 more tri­als flop

You can write off just about all of the re­main­ing val­ue as­signed to As­traZeneca’s asth­ma drug tralok­inum­ab — if you hadn’t al­ready done so. Out­side of the can­cer are­na, As­traZeneca’s string of set­backs is con­tin­u­ing.

The phar­ma gi­ant fol­lowed up yes­ter­day’s news that its BTK drug Calquence (acal­abru­ti­nib) had scored an ear­ly ap­proval at the FDA with a note writ­ing off the last two Phase III stud­ies of their IL-13 drug tralok­inum­ab as fail­ures.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.